Innovest Global, Inc. (OTCPK:IVST) acquired remaining 80% stake in StemVax, LLC on February 1, 2020. As part of Innovest Global's business strategy, StemVax will thrive as a stand-alone public company once spun out from Innovest Global in mid-2020. Innovest Global's biotech division upon spin out will continue to be led as Chief Executive Officer by Dwain Irvin, Founder of StemVax, and supported by his growing scientific team. Dan Martin, Chairman and Chief Executive Officer of Innovest Global, will also act as Chairman of the Board of Directors for the new entity representing shareholder interests. Innovest Global, Inc. (OTCPK:IVST) completed the acquisition of remaining 80% stake in StemVax, LLC for $0.05 million on February 1, 2020. Under the terms of consideration, Innovest Global issued 7.5 million warrants with a price of $0.16 a share.